GeneDx Holdings Corp.
WGSHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, GeneDx Holdings Corp. focuses on Diagnostics & Research services and products. GeneDx Holdings Corp., a genomics company, provides genetic testing services. With a market capitalization of $2.56B, it sits in mid-cap territory. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Market Cap
$2.56B
Beta
2.01
P/E (TTM)
—
P/E (Fwd)
73.57
EPS (TTM)
$-3.58
EPS (Fwd)
$1.17
ROE
-40.8%
ROA
-7.9%
Cash
$132.5M
Total Debt
$167.4M
Free CF
-$47.5M
52W Change
-32.4%
Annual Financials
Cash vs Debt
Where WGS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, WGS finished 26.30% above its 150-day moving average ($68.66) and 1.74% above its 200-day moving average ($85.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is WGS overbought or oversold?
At the September 3, 2026 close, WGS's RSI(14) was 63.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, WGS has $132.5M in cash with $167.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$47.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -40.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $234.7M (2022) to $427.5M (2025), reflecting a 82% increase over the period.
With a beta above 1.5, WGS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing WGS.